A Phase I/II study of ONO-5163 in patients with secondary hyperparathyroidism under maintenance dialysis
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 01 Aug 2017 Results published in the Clinical Nephrology
- 29 Jun 2016 Planned number of patients changed from 55 to 61.
- 24 May 2016 According to an Ono Pharmaceutical media release, results from this study were presented at the 53rd European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress.